MX2015011945A - Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. - Google Patents

Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.

Info

Publication number
MX2015011945A
MX2015011945A MX2015011945A MX2015011945A MX2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A
Authority
MX
Mexico
Prior art keywords
mrna
messenger rna
quantitative assessment
complex
specific binding
Prior art date
Application number
MX2015011945A
Other languages
English (en)
Inventor
Michael Heartlein
Frank Derosa
Anusha Dias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2015011945A publication Critical patent/MX2015011945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens

Abstract

La presente invención proporciona, entre otros, métodos para cuantificar la eficacia de la formación de casquetes de ARNm, particularmente ARNm sintetizado in Vitro; en algunas modalidades, los métodos de acuerdo con la presente invención comprenden proporcionar una muestra de ARNm que contiene ARNm con casquete y sin casquete, proporcionar una sustancia de unión específica al casquete en condiciones que permiten la formación de un complejo entre la sustancia de unión específica al casquete y el ARNm con casquete; y determinar cuantitativamente la cantidad del complejo en comparación con un control, y cuantificar de ese modo la eficacia de la formación de casquetes de ARNm.
MX2015011945A 2013-03-14 2014-03-14 Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. MX2015011945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784253P 2013-03-14 2013-03-14
PCT/US2014/027602 WO2014152673A1 (en) 2013-03-14 2014-03-14 Quantitative assessment for cap efficiency of messenger rna

Publications (1)

Publication Number Publication Date
MX2015011945A true MX2015011945A (es) 2015-12-01

Family

ID=50625146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011945A MX2015011945A (es) 2013-03-14 2014-03-14 Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.

Country Status (13)

Country Link
US (3) US10626439B2 (es)
EP (2) EP3495505A1 (es)
JP (1) JP2016515216A (es)
CN (1) CN105209633A (es)
AU (1) AU2014239264A1 (es)
BR (1) BR112015022141A2 (es)
CA (1) CA2903488A1 (es)
DK (1) DK2971098T3 (es)
EA (1) EA201591286A1 (es)
ES (1) ES2708562T3 (es)
MX (1) MX2015011945A (es)
TR (1) TR201901396T4 (es)
WO (1) WO2014152673A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
DK3336082T3 (da) 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
CN111671918A (zh) 2011-06-08 2020-09-18 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
ES2680595T3 (es) 2013-03-14 2018-09-10 Translate Bio, Inc. Evaluación cuantitativa para eficacia de ARN mensajero para tapar
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
TR201901310T4 (tr) 2013-03-14 2019-02-21 Translate Bio Inc Mesajcı RNA'nın saflaştırılması yöntemleri.
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JP2017522028A (ja) 2014-07-16 2017-08-10 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 環状ポリヌクレオチド
SE539096C2 (en) * 2015-03-18 2017-04-04 C Conjunction Ab A method, system and software application for providing context based commercial information
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
SI4140491T1 (sl) 2015-09-21 2024-01-31 Trilink Biotechnologies, Llc Postopek sinteze 5'-omejenih RNK
AU2016338559B2 (en) 2015-10-14 2022-11-24 Translate Bio, Inc. Modification of RNA-related enzymes for enhanced production
WO2017066797A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017066793A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017098468A1 (en) * 2015-12-09 2017-06-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
ES2941411T3 (es) 2016-05-18 2023-05-22 Modernatx Inc Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos
GB201615233D0 (en) * 2016-09-08 2016-10-26 Bbi Solutions Oem Ltd Solid Phase Conjugate
EP3971291A1 (en) 2017-02-27 2022-03-23 Translate Bio, Inc. Methods for purification of messenger rna
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
DK3585892T3 (da) 2017-02-27 2022-08-22 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
CN111032863A (zh) * 2017-06-30 2020-04-17 科德克希思公司 T7 rna聚合酶变体
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
CA3114892A1 (en) * 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
CA3113271A1 (en) * 2018-10-26 2020-04-30 Illumina, Inc. Modulating polymer beads for dna processing
EP3877538A1 (en) 2018-11-08 2021-09-15 Translate Bio, Inc. Methods and compositions for messenger rna purification
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
KR20220029556A (ko) 2019-05-15 2022-03-08 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
MX2022001870A (es) 2019-08-14 2022-05-30 Curevac Ag Combinaciones y composiciones de arn con propiedades inmunoestimuladoras disminuidas.
CN112626177A (zh) * 2019-10-09 2021-04-09 华中科技大学 一种快速定量检测rna加帽效率的方法
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
CN116113422A (zh) * 2020-06-26 2023-05-12 凯瑞斯马治疗公司 免疫细胞的mRNA转染
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN113337559A (zh) * 2020-08-20 2021-09-03 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
CA3230056A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
CN117730157A (zh) * 2022-04-15 2024-03-19 萨默费尼根有限公司 用于定量监测mRNA加帽效率的方法
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN116426610B (zh) * 2023-06-08 2024-01-05 启辰生生物科技(珠海)有限公司 一种LC-MS法准确定量mRNA加帽效率的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
DE4140463A1 (de) 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
AU4966997A (en) 1996-11-18 1998-06-10 Takeshi Imanishi Novel nucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
EP2341057A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
EP1214331B1 (en) 1999-08-30 2006-10-11 Roche Diagnostics GmbH 2-azapurine compounds and their use
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
US20020197622A1 (en) 2001-01-31 2002-12-26 Mcdevitt John T. Method and apparatus for the confinement of materials in a micromachined chemical sensor array
DE60327775D1 (de) * 2002-06-24 2009-07-09 Exiqon As Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
WO2007120863A2 (en) 2006-04-14 2007-10-25 Epicentre Technologies Kits and methods for generating 5' capped rna
JP2009544754A (ja) 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US20100035249A1 (en) * 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
ES2680595T3 (es) 2013-03-14 2018-09-10 Translate Bio, Inc. Evaluación cuantitativa para eficacia de ARN mensajero para tapar
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
CN112153985B (zh) 2018-04-25 2024-03-01 埃泽瑞斯公司 用于颗粒制剂的防冻剂

Also Published As

Publication number Publication date
BR112015022141A2 (pt) 2017-08-29
EP2971098A1 (en) 2016-01-20
JP2016515216A (ja) 2016-05-26
US10626439B2 (en) 2020-04-21
US20160002705A1 (en) 2016-01-07
CA2903488A1 (en) 2014-09-25
US20210371900A1 (en) 2021-12-02
US11104934B2 (en) 2021-08-31
US11920182B2 (en) 2024-03-05
EP3495505A1 (en) 2019-06-12
ES2708562T3 (es) 2019-04-10
EP2971098B1 (en) 2018-11-21
CN105209633A (zh) 2015-12-30
WO2014152673A1 (en) 2014-09-25
US20200318156A1 (en) 2020-10-08
DK2971098T3 (en) 2019-02-18
EA201591286A1 (ru) 2016-02-29
TR201901396T4 (tr) 2019-02-21
AU2014239264A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
MX2015011945A (es) Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
MX2015011944A (es) Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
PH12020551028A1 (en) Methods, kits and apparatus for expanding a population of cells
GB2511221A (en) Methods and compositions for classification of samples
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
MX341204B (es) Metodo para caracterizar almenos un microorganismo por medio de espectrometria de masa.
PH12014502581B1 (en) Aptamer-based multiplexed assays
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
MA38500A1 (fr) Systèmes et procédés pour analyser une nourriture pour animal
MX2015013310A (es) Metodo y reactivo para determinar metabolitos de la vitamina d.
EP3009454A3 (en) Antibodies specific to cadherin-17
GB201014028D0 (en) In-situ reagent
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
BR112016000231A8 (pt) métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
GB2495884A (en) A method of increasing the effect of an activated-potentiated form of an antibody
MX2017011198A (es) Biomarcadores para preeclampsia.
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
GB201317680D0 (en) Representation of spatial-frequency data as a map
GB201119585D0 (en) Assay
MX2016007148A (es) Metodos de ensayo de beta-glucano.
MY182547A (en) Polymerase chain reaction detection system
MX2022000627A (es) Metodo para determinar al menos un parametro de una composicion de muestra que comprende acido nucleico, tal como arn, y opcionalmente particulas.
EP2811281A4 (en) COMPOSITION FOR ENHANCING A BIOLOGICAL SAMPLE, PROCESS FOR PREPARING A PARAFFIN BLOCK USING THE SAME, AND PROCESS FOR PREPARING A CELL BLOCK TEST FROM THE PARAFFIN BLOCK TO FORM A CELL MICROMATOR